The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2
- PMID: 1733448
- PMCID: PMC1977346
- DOI: 10.1038/bjc.1992.18
The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2
Abstract
The toxicity due to interleukin-2 (IL-2) strongly resembles the clinical picture seen during septic shock. In septic shock activation of polymorphonuclear neutrophils (PMN) and the complement system contribute significantly to the pathophysiology of the condition. We therefore investigated whether similar events contributed to the toxicity observed with IL-2. Four patients received seven cycles of escalating dose IL-2 (18.0 to 72.0 X 10(6) IU m-2 day-1) and 16 were treated with 20 cycles of fixed dose IL-2 (12.0 or 18.0 X 10(6) IU m-2 day-1). Toxicity, as judged by hypotension (P = less than 0.005) and capillary leakage (fall in serum albumin 18.2 vs 4.0 gm l-1; P = less than 0.0005 and weight gain 4.0 vs 1.2 kg; P = less than 0.025) were worse with the esc. dose protocol. PMN became activated following IL-2 with mean peak elastase/alpha 1-antitrypsin (E alpha 1 A) and lactoferrin values of 212 (SEM = 37) and 534 (SEM = 92) ng ml-1 respectively occurring 6 h after the IL-2. Peak values for the esc. dose IL-2 group being generally higher than 500 ng ml-1. Activation of the complement cascade was evidenced by a dose dependent elevation of peak C3a values (fixed dose 9.1 (SEM = 0.6); esc. dose 25.7 (SEM = 6.33); P = less than 0.005) on day 5 of IL-2. There was a significant correlation between C3a levels and the degree of hypotention during the first 24 h after IL-2 (r = 0.91) and parameters of capillary leakage such as weight gain and fall in serum albumin (r = 0.71). These data suggest that activation of PMN initiates endothelial cell damage which subsequently leads to activation of the complement cascade. This latter system then contributes to the haemodynamic changes and capillary leakage seen in IL-2 treated patients.
Similar articles
-
A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.Br J Cancer. 1994 Mar;69(3):596-8. doi: 10.1038/bjc.1994.109. Br J Cancer. 1994. PMID: 8123494 Free PMC article.
-
Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2.Br J Cancer. 1996 Oct;74(8):1297-301. doi: 10.1038/bjc.1996.533. Br J Cancer. 1996. PMID: 8883421 Free PMC article. Clinical Trial.
-
[Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].Anaesthesist. 1996 Dec;45(12):1171-8. doi: 10.1007/s001010050354. Anaesthesist. 1996. PMID: 9065251 Clinical Trial. German.
-
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.Dan Med J. 2013 Dec;60(12):B4774. Dan Med J. 2013. PMID: 24355457 Review.
-
Interleukin-2 therapy of cancer-clinical perspectives.Int Immunopharmacol. 2021 Sep;98:107836. doi: 10.1016/j.intimp.2021.107836. Epub 2021 Jul 1. Int Immunopharmacol. 2021. PMID: 34218217 Review.
Cited by
-
Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.J Transl Med. 2014 May 13;12:127. doi: 10.1186/1479-5876-12-127. J Transl Med. 2014. PMID: 24884532 Free PMC article. Review.
-
Determination of capillary leakage due to recombinant interleukin-2 by means of noninvasive conductivity measurements.Eur J Appl Physiol Occup Physiol. 1993;67(2):168-73. doi: 10.1007/BF00376662. Eur J Appl Physiol Occup Physiol. 1993. PMID: 8223524
-
Clinical toxicity of cytokines used as haemopoietic growth factors.Drug Saf. 1995 Dec;13(6):371-406. doi: 10.2165/00002018-199513060-00006. Drug Saf. 1995. PMID: 8652081 Review.
-
Monitoring of immunotherapy with cytokines or monoclonal antibodies.Cytotechnology. 1995 Jan;18(1-2):93-106. doi: 10.1007/BF00744324. Cytotechnology. 1995. PMID: 22358641
-
Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro.Inflammation. 1996 Aug;20(4):361-72. doi: 10.1007/BF01486739. Inflammation. 1996. PMID: 8872500
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical